FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) for to include 3 new indications including treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE

Newsletter